Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 75 Future 3-5Y EPS without NRI Growth Rate is 4.94 as of Aug. 29, 2026. GuruFocus rates CSSPF with a GF Score™ of 75/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 281 Medical Devices & Instruments companies, NIOX Group ranks worse than 95.73% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, NIOX Group's Future 3-5Y EPS without NRI Growth Rate is 4.94.
NIOX Group (OTCPK:CSSPF) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
NIOX Group Future 3-5Y EPS without NRI Growth Rate Related Terms
CSSPF vs ABT, SYK, MDT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, NIOX Group's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where NIOX Group's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 4.94 mean?
NIOX Group (CSSPF) has a Future 3-5Y EPS without NRI Growth Rate of 4.94 as of Aug. 29, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #269 out of 281 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is NIOX Group's Future 3-5Y EPS without NRI Growth Rate too high?
NIOX Group's current Future 3-5Y EPS without NRI Growth Rate is 4.94. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.96. NIOX Group's value of 4.94 is 76.4% below this industry median. Based on the distribution chart, NIOX Group ranks #269 out of 281 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NIOX Group has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Future 3-5Y EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #269 out of 281 companies for Future 3-5Y EPS without NRI Growth Rate. This places NIOX Group in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.96. NIOX Group's value of 4.94 is 76.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.96, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Future 3-5Y EPS without NRI Growth Rate of 4.94 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Future 3-5Y EPS without NRI Growth Rate is 4.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.82 — trading 32.2% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 4.94 and 76.4% below the Medical Devices & Instruments industry median of 20.96. NIOX Group's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Future 3-5Y EPS without NRI Growth Rate is 4.94 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 32.2% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Future 3-5Y EPS without NRI Growth Rate: 4.94
GF Value™: $1.21 vs. price of $0.82 (32.2% below fair value)
Industry Position: 76.4% below the Medical Devices & Instruments median (#269 of 281)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
75GF Score
Get the complete analysis for CSSPF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
